During the past decade, EPS Corporation conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "EPS Corporation" are "Colorectal Cancer" (1 trials), "Liver Metastasis" (1 trials) and "Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer" (1 trials). Many other conditions were trialed in "EPS Corporation" in a lesser frequency.

Most popular intervention types in "EPS Corporation" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "5-FU" (2 trials), "Bevacizumab" (2 trials), "Cetuximab" (2 trials), "L-OHP" (2 trials) and "l-LV" (2 trials). Other intervention names were less common.

The vast majority of trials in "EPS Corporation" are 2 trials for "All" genders.

Currently, there are NaN active trials in "EPS Corporation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in EPS Corporation, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in EPS Corporation, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".